APELLIS PHARMACEUTICALS, INC

Prevent Blindness announces Dec 2-8, 2024, as Geographic Atrophy (GA) Awareness Week, offering free resources on GA, an advanced form of dry AMD affecting ~1M in the US. Funded by Apellis Pharmaceuticals, resources include fact sheets, social media graphics, expert-led videos, and the Living Well With Low Vision program. Risk factors for GA include family history, age, race, and lifestyle choices. Prevent Blindness encourages patients to use their resources and consult eye doctors for optimal treatment plans.

AI in OCT analysis outperforms human experts in predicting GA progression, with accuracy of 0.48 and c-index of 0.69. AI-based analysis in OAKS and DERBY trials showed therapeutic reductions in RPE and EZ loss, emphasizing the impact of EZ-RPE difference on disease progression and response.

Apellis Pharmaceuticals reports $196.8 million Q3 2024 revenue, driven by SYFOVRE and EMPAVELI sales. The company faces market, operational, and regulatory risks, including a CHMP negative opinion on SYFOVRE in Europe. Apellis plans to submit FDA and EMA applications for systemic pegcetacoplan in 2025, and is developing APL-3007 and an oral complement inhibitor.

Pegcetacoplan showed 68% proteinuria reduction (p<0.0001) vs. placebo, stabilized eGFR, and 71% zero C3c staining intensity in C3G and IC-MPGN patients, with consistent results across subgroups and a favorable safety profile.

Pegcetacoplan showed 68% proteinuria reduction (p<0.0001) vs. placebo, with effects observed from Week 4. It also stabilized eGFR and reduced C3c staining, with 71% achieving zero C3c intensity. Results were consistent across subgroups, including C3G, IC-MPGN, adolescents, adults, and native/post-transplant kidneys.

The 'Complement 3 Glomerulopathy - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides insights on 3+ companies and 3+ pipeline drugs for C3G, covering drug profiles, therapeutic assessment, and pipeline development activities.

Apellis Pharmaceuticals announces Caroline Baumal, M.D., as new chief medical officer, replacing Federico Grossi, M.D., Ph.D., who will assist with transition until February 28, 2023.

The biotech industry, valued at $1.2 trillion, faces challenges post-pandemic with reduced revenues, regulatory pressures, and decreased FDA approvals. Funding has significantly dropped, impacting innovation. In 2023, biotech stocks like Jazz Pharmaceuticals, Incyte Corporation, and Ultragenyx Pharmaceutical are among the worst performers, with significant YTD share price declines.